T he manner in which species and indeed individuals handle ivermectin may vary considerably. The response of the parasite depends therefore on its location i.e. skin, nodule, blood or lymphatics and numerous hosts factors (Schulz-Key et al., 1993) and levels of free drug impinding on vital organelles of the worm. Pharmacokinetic parameters and free drug worm levels should be investigated for animal models of filariaris and new filaricides. T n West Africa, control of onchocerciasis by the _ Onchocerciasis Control Programme (OCP) relies on both vector eradication and chemotherapy (Remme et al., 1990a (Remme et al., , 1990b . Ivermectin, the drug of choice, is highly effective against microfilariae of Onchocerca volvulus ; a single oral dose achieves a rapid elimination and a long lasting suppression of microfilaridermia (Greene et al., 1985 Article available at http://www.parasite-journal.org or http://dx.doi.org/10.1051/parasite/199401s1028 ment makes ivermectin applicable for community-based mass treatment campaigns (White et al., 1987) . In most areas of the OCP the combined control measures have indeed reduced the risk of O. volvulus infection and onchocerciasis-associated blindness. However, in borderline areas, such as central Togo, the risk of re-infection and evo lution of ocular pathology still remains high (De Sole et al., 1992) .
In order to study the feasibility, compliance and efficacy of mass treatment in the field we performed annual mass treatment campaigns in six meso-to hyperendemic villages in central Togo. More than 3,000 inhabitants received annually a blanket treatment with 150pg ivermectin/kg body weight. The effect of this control strategy on preva lence of onchocerciasis, on community microfilarial load (CMFL) and on the evolution and progression of ocular pathology induced by O. volvulus infection, has been eva luated over a period of 4 years. In addition, since 8 years, a group of 200 onchocerciasis patients from the same vil lages, who volunteered to participate in an ivermectin dose-finding study, have been treated and examined annually.
Under consideration of exclusion criteria, disease and refu sal about 70 % of the population received the annual treat ment with ivermectin. The densities of O. volvulus microfilariae (mf) in treated patients remained significantly reduced, and the number of patients with a subclinical infection, i.e. permanently negative for mf of O.
volvulus, increased following repeated ivermectin therapy. The num ber of treated patients per village with moderate or severe side reactions decreased following each annual treatment. In those patients who received ivermectin regularly dtiring the last 8 years onchocerciasis-associated ocular pathology clearly diminished (e.g. punctate keratitis, sclerosing kerati tis, uveitis, limbitis) or remained at pre-treatment levels (e.g. chorioretinitis, papillitis). In contrast, in those patients who received ivermectin treatment only occasionally the onchocerciasis-associated ocular pathology progressed often to irreversible eye damage, and in some cases to blindness.
In summary, despite the location of our study in an area of the OCP where, however, the risk of re-infection and blind ness remains high, we conclude that progression of ocular pathology in chronic onchocerciasis can only be prevented by regular treatments with ivermectin. Ovl.9 : a 19,000 Mr antigen identified using a rabbit serum raised against material extracted from the surface of adult worms by treatment with mercaptoethanol (Engelbrecht et al, 1991) . The 512 bp insert has been sequenced and no homology could be found with any other cloned molecule. Measurement (by ELISA) of anti-Ovl.9 antibodies in sera collected from onchocerciasis patients revealed a correla tion between high IgG4 levels and presentation of skin disease (Engelbrecht et al., 1991) . These IgG4 responses appeared to be enhanced after treatment with ivermectin. Ov2.5 : a 50,000 Mr antigen which was selected on the basis of its reactivity with a rabbit antiserum against mate rial extracted from the surface of adult worms by treatment with mercaptoethanol (Engelbrecht et al., 1991) . No sequence homology could be found with any other cloned molecule. Ov3.11 : a 42,000 Mr antigen identified using a rabbit sera raised against O. volvulus L3 larvae.
USE OF THE LITOMOSOIDES SIGMODONTIS -MOUSE MODEL IN DEVELOPMENT OF AN
OvHSP : The heat-shock protein 70 of O. volvulus. This cDNA clone (4l0bp, all coding) codes for the C-terminal end of the protein. Sequence analysis revealed almost 100 % homology with Brugia malayi HSP70 ; 76 % homology with human cognate HSP70 ; and 75 % identity with human HSP70. Despite the overall high homology of parasite and host HSPs, a short sequence of 12 amino acids unique to the parasite was identified. It is predicted that this region, which is proximal to the C-terminus contains 2 non-conser ved changes and 4 conserved changes, has a secondary structure and B cell epitope not found in host HSPs.
The OvHSP sequence was sub-cloned into the expression vector pTrcHis, a vector that allows purification of fusion proteins over Ni affinity columns through the interaction with a polyhistidine sequence contained in the carrier peptide.
A rabbit antiserum raised against the recombinant OvHSP was used in histochemical experiments to localise the anti gen in adult worm sections. The most heavily stained struc tures were ova.
Human antibody responses directed against the recombinant HSP70 molecule AND a synthetic peptide representing the 12 amino acid filarial specific region of HSP70 are being investigated. As shown in Figure 1 , ELISA performed using
